Underweight XOM: Trim 30-40% at $164 to convert bearish MACD cross, double rejection at $166.15, and peak refining margins into actionable alpha while retaining 60-70% core
Underweight conviction is warranted by converging bearish signals: MACD has bearish crossed (2.12 below signal 2.51, histogram -0.39), two rejections at $166.15 with declining volume (12.9M vs 18.95M August breakout), receivables +69% vs revenue +44% representing ~$9B capital absorption at commodity cycle inflection risk, Q2'26 EPS $3.48 at peak refining margins with 71% sequential swing from Q1's $1.00 anchoring forward PE 15.2x to potentially mean-reverting earnings. The 30-40% trim range is optimal based on prior decision history: 60-70% retention captured +1.3% and +2.7% alpha on 9/4 and 9/8 respectively while structural floor (0.175 beta, $20.67B TTM FCF, 0.47x net debt/EBITDA, 41-year dividend streak) prevented downside the technical breakdown implied. 4-8 week price target is $153 (50 SMA) with $142 (200 SMA) as bear-case scenario; use $158 GTC limit order for first re-entry tranche. Underweight extends if receivables track toward $45-50B and effective tax rate normalizes above 28% at Q3 earnings.
| Position | Action |
|---|---|
| Trim 30-40% of XOM position at current $164 | Sell 30-40% of XOM shares |
| Retain 60-70% core position for dividend carry and defensive characteristics | Hold 60-70% of XOM shares |
| First re-entry tranche: price reaches $158-160 | Buy back 1/3 of trimmed shares at $158-160 (10 EMA/VWMA confluence zone) |
| Second re-entry tranche: price reaches $155-156 | Buy back 1/3 of trimmed shares at $155-156 (lower Bollinger and recent swing low zone) |
| Final re-entry tranche: confirmed close above $167.81 on volume >15M shares | Buy back remaining 1/3 of trimmed shares on confirmed breakout above $167.81 with volume >15M shares |
| Price falls to $150 on retained core | Stop out retained core position at $150 |
XOM offers the cleanest risk-adjusted opportunity in today's market through record earnings, multiple expansion as forward PE compresses from 21.1x to 15.2x, a 5.5% total shareholder yield, defensive 0.175 beta with commodity upside, and structural operational momentum in Guyana, Permian, and Angola.
| Indicator | Value | Signal |
|---|---|---|
| 50 SMA | 153.37 (price +7.1% above) | bullish |
| 200 SMA | 143.54 (price +14.4% above) | bullish |
| 10 EMA | 161.64 (price +1.6% above, recently reclaimed) | bullish |
| RSI(14) | 59.39 | neutral |
| Bollinger Upper Band | 167.81 | neutral |
| Bollinger Lower Band | 155.26 | neutral |
| Bollinger Mid Band (20 SMA) | 161.53 | neutral |
| MACD | 2.12 (signal line: 2.51) | bearish |
| MACD Histogram | -0.39 | bearish |
| ATR | 3.54 (~2.2% of price) | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
Then: Buy 1/3 of trimmed shares; use GTC limit order at $158
The receivables increase is proportional to revenue growth, not a cash conversion warning
EV: +7.5% to retest 52-week high at $176.41 · concedes: MACD bearish cross is a legitimate yellow flag; Kazakhstan $5.06B arbitration is live; Venezuela policy is messy; Energy transition is a long-term overhang; Q1'26 was unusually weak at $1.00 EPS creating a dramatic comparison
XOM at $164 is a geopolitical premium at peak earnings with asymmetric downside risk and mean-reverting fundamentals that make it a SELL/AVOID at current levels.
EV: ~−0.9% · concedes: Guyana, Permian, Angola, and LNG assets are real; Dividend is a reason to hold in diversified portfolio; XOM is a great company; Buy at $150 or $135 could be attractive
→ vs conservative: Holding full position at $164 is paying full price for defensive characteristics that were available cheap at $135; low beta limits upside capture while remaining exposed to downside when oil mean-reverts; the 43-year dividend streak and 16% debt-to-equity are irrelevant at current valuation levels
→ vs neutral: Waiting for daily close above 167.81 with expanding volume during a stagflationary regime is a low-probability bet; if it works, upside is only 170-172 before next major resistance; if it fails, 50 SMA at 153 represents fast drawdown in oil names that don't bleed—they crater
→ vs neutral: 'Patient accumulation' narrative is the same thesis as the trim (wait for pullback to 155-158), but waiting with 100% of position on means paying maximum price for being wrong; the aggressive move is to trim now and have powder ready
| VWMA | 161.82 | bullish |
Support: 153.37 · 155.26 · 160.5 · 161.64 · 161.82 | Resistance: 165.18 · 167.81 · 170
XOM trades at 164.23, holding firmly above all key moving averages (200 SMA at 143.54, 50 SMA at 153.37, 10 EMA at 161.64) in a structurally intact uptrend that has delivered ~56% gains over 13 months. The primary short-term concern is a fresh MACD bearish cross (histogram -0.39) combined with below-average volume (12.9M vs ~19M peak), suggesting momentum is cooling rather than reversing. The 50 SMA, VWMA, and 10 EMA converge near 161.50-162, offering high-conviction dip-buy zones, while 167.81 (upper Bollinger band) is the key breakout level to watch for a momentum reset. Risk management anchors to ATR-based stops at ~160.50 or structural stops below 155.26 (lower band).
Market Cap
$675.30B
PE Ratio (TTM)
21.11x
Forward PE
15.22x
PEG Ratio
1.37
Price / Book
2.60x
EPS (TTM)
$7.78
Forward EPS
$10.79
Dividend Yield
2.56%
Book Value / Share
$63.08
Revenue (TTM)
$361.06B
Gross Profit
$107.48B
Gross Margin
~29.8%
EBITDA (TTM)
$67.94B
EBITDA Margin
~18.8%
Operating Income
~$57.26B
Operating Margin
15.86%
Net Income (TTM)
$32.76B
Profit Margin
9.07%
ROE
12.58%
ROA
5.52%
Free Cash Flow (TTM)
$20.67B
Total Assets
$464.48B
Total Equity
$259.38B
Total Debt
$42.37B
Net Debt
$31.78B
Debt/Equity
~16.3%
Current Ratio
1.135
Working Capital
$11.96B
Receivables
$60.56B
52-Week High
$176.41
52-Week Low
$110.39
50-Day MA
$153.44
200-Day MA
$144.95
Beta
0.175
Q2'26 Revenue
$114.53B
Q2'26 EBITDA
$28.34B
Q2'26 Net Income
$14.53B
Q2'26 Diluted EPS
$3.48
Annual Buybacks
~$20B
Annual Dividends
~$17B
Total Shareholder Yield
~5.5%
Strengths
Concerns
ExxonMobil delivered an exceptional Q2 2026 with revenue of $114.53B (+44% YoY), net income of $14.53B (+105% YoY), and diluted EPS of $3.48 (+112% YoY) — the highest single-quarter print in the dataset. The company maintains a fortress balance sheet with $464.48B in assets, $259.38B in equity, and a very low Debt/Equity ratio of 16.3%. With TTM free cash flow of $20.67B and a 2.56% dividend yield supplemented by ~$20B annualized buybacks, total shareholder yield approximates 5.5%. The stock trades at a forward PE of 15.22x with a defensive beta of 0.175, suggesting constructive positioning if Q3'26 confirms the Q2 inflection as a structural earnings reset rather than a transient spike.
Macro: U.S.-Iran conflict dominates as the primary driver; Houthi strikes on Saudi Aramco facilities (73 wounded) have pushed Brent back above $100/bbl, with Iran warning of further Gulf oil and gas infrastructure targeting. U.S. actively striking Iranian tankers. Stagflationary macro regime: Polymarket prices 93% probability of NO Fed rate cuts in 2026 (up 4pp in a week on $8.2M volume), with all sub-distributions for cuts at 0%. U.S. recession by end of 2026 priced at only 8% (down from prior readings). Morgan Stanley (Mike Wilson) flagged higher oil and higher rates as the main near-term risks to U.S. equities. FRED macro data unavailable (API key not configured); macro narrative constructed from prediction-market pricing and news flow only.